EA201791443A1 - Естественные киллерные клетки и их применения - Google Patents

Естественные киллерные клетки и их применения

Info

Publication number
EA201791443A1
EA201791443A1 EA201791443A EA201791443A EA201791443A1 EA 201791443 A1 EA201791443 A1 EA 201791443A1 EA 201791443 A EA201791443 A EA 201791443A EA 201791443 A EA201791443 A EA 201791443A EA 201791443 A1 EA201791443 A1 EA 201791443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
methods
natural killer
applications
killer cells
Prior art date
Application number
EA201791443A
Other languages
English (en)
Russian (ru)
Inventor
Брайан Мерфи
Ванесса Воскинарян-Берсе
Андреа Нордберг
Кейт Уилсон
Линь КАН
Original Assignee
Антродженезис Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антродженезис Корпорейшн filed Critical Антродженезис Корпорейшн
Publication of EA201791443A1 publication Critical patent/EA201791443A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201791443A 2014-12-31 2015-12-30 Естественные киллерные клетки и их применения EA201791443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098560P 2014-12-31 2014-12-31
PCT/US2015/068055 WO2016109661A1 (en) 2014-12-31 2015-12-30 Natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
EA201791443A1 true EA201791443A1 (ru) 2018-01-31

Family

ID=56285039

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791443A EA201791443A1 (ru) 2014-12-31 2015-12-30 Естественные киллерные клетки и их применения

Country Status (12)

Country Link
US (2) US20180008637A1 (https=)
EP (1) EP3240552A4 (https=)
JP (3) JP2018502115A (https=)
KR (2) KR20230146101A (https=)
CN (1) CN107405364A (https=)
AU (2) AU2015374055A1 (https=)
BR (1) BR112017014269A2 (https=)
CA (1) CA2972662A1 (https=)
EA (1) EA201791443A1 (https=)
IL (1) IL253248A0 (https=)
NZ (1) NZ733213A (https=)
WO (1) WO2016109661A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
EP3350316B1 (en) * 2015-09-15 2024-05-08 Stichting Radboud universitair medisch centrum IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
US20200179341A1 (en) * 2016-11-04 2020-06-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
JP2020503043A (ja) * 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112020003116A2 (pt) * 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
WO2019059713A2 (ko) * 2017-09-21 2019-03-28 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
CN112135618A (zh) * 2018-02-20 2020-12-25 蒙特利尔大学 体内介导免疫应答的nk和dc细胞的扩增
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
KR20210016567A (ko) 2018-05-30 2021-02-16 글리코스템 떼라퓨틱스 비.브이. Car nk 세포
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US20220025327A1 (en) * 2018-10-01 2022-01-27 Universiteit Gent Accelerated human hematopoeitic stem cell differentiation towards mature natural killer cells with enhanced antibody-dependent cytotoxic activity
CN109294985B (zh) * 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2019387491A1 (en) * 2018-11-30 2021-05-27 Celularity Inc. Expansion of natural killer cells and ILC3 cells with novel aromatic compounds
WO2020124256A1 (en) * 2018-12-21 2020-06-25 Stemcell Technologies Canada Inc. Media and methods for differentiating natural killer cells
JP7335001B2 (ja) * 2019-01-18 2023-08-29 アセポディア バイオテクノロジーズ リミテッド 新規ｃｄ１６＋ナチュラルキラーおよびｃｄ１６＋ナチュラルキラー細胞の培養方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
KR102298639B1 (ko) * 2019-03-28 2021-09-07 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
US20220265712A1 (en) * 2019-06-14 2022-08-25 Celularity Inc. Populations of natural killer cells for treating cancers
CN113652393B (zh) * 2020-05-12 2023-08-15 内蒙古大学 一种提高牛胚胎干细胞多能性的方法
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113046314B (zh) * 2021-03-30 2022-11-25 中国科学技术大学 一种人脐血或骨髓造血干细胞体外诱导扩增蜕膜样自然杀伤细胞的方法
CN113337466B (zh) * 2021-07-13 2023-03-24 杭州原生生物科技有限公司 一种无血清nk分化培养基及其制备方法
CN115381959A (zh) * 2022-09-30 2022-11-25 上海纳米技术及应用国家工程研究中心有限公司 一种治疗肝癌的联合用药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666746T3 (es) * 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
EP2807165B1 (en) * 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
DK2812011T3 (da) * 2012-02-08 2020-02-24 Glycostem Therapeutics B V Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP2015526088A (ja) * 2012-08-13 2015-09-10 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用

Also Published As

Publication number Publication date
IL253248A0 (en) 2017-08-31
WO2016109661A1 (en) 2016-07-07
EP3240552A4 (en) 2018-06-20
KR20170098938A (ko) 2017-08-30
US20200330516A1 (en) 2020-10-22
JP2023022037A (ja) 2023-02-14
AU2021282387A1 (en) 2021-12-23
US20180008637A1 (en) 2018-01-11
JP2021072786A (ja) 2021-05-13
CA2972662A1 (en) 2016-07-07
AU2015374055A1 (en) 2017-07-20
CN107405364A (zh) 2017-11-28
JP2018502115A (ja) 2018-01-25
BR112017014269A2 (pt) 2018-03-27
KR20230146101A (ko) 2023-10-18
EP3240552A1 (en) 2017-11-08
NZ733213A (en) 2022-10-28

Similar Documents

Publication Publication Date Title
EA201791443A1 (ru) Естественные киллерные клетки и их применения
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
MX2025003310A (es) Integracion dirigida de acidos nucleicos
WO2014028453A3 (en) Natural killer cells and uses thereof
MX2021006398A (es) Expansión de células asesinas naturales y células ilc3 con compuestos aromáticos novedosos.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2025015455A (es) Metodos biologicos para preparar terpenos
EA201790413A1 (ru) Антитела против tigit
MX342995B (es) Métodos de generar células asesinas naturales.
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
MY184889A (en) T cell activating bispecific antigen binding molecules
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
MX2017002081A (es) Metodo para tratar cancer de cuello uterino.
WO2017048809A8 (en) Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
MX2021009554A (es) Produccion de virus en cultivos celulares.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
AU2018253575A1 (en) Natural killer cells from placenta
EA201691953A1 (ru) Белки тонопласта, функционирующие как протон/сахар-антипортеры, и их использование для повышения концентрации сахарозы в запасающем сахарозу органе растений
EA201690232A1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
CY1115803T1 (el) Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα